A HIGHER FRACTION OF DRUG RESISTANT PROVIRUSES EXPRESS UNSPLICED HIV RNA DURING ART COMPARED TO THE ARCHIVAL WILD-TYPE PROVIRUSES THAT COMPRISE THE HIV-1.

Slides:



Advertisements
Similar presentations
POSTER 82 CXCR4 using HIV-1 strains more abundant in PBMC than in plasma Chris Verhofstede 1 *, Linos Vandekerckhove 2, Veerle van Eygen 3, Kenny Dauwe.
Advertisements

Measuring the latent HIV Reservoir
Hiromi Imamichi, Robin L. Dewar, Da Wei Huang, Dun Liang, Catherine R. Rehm, Ellen Paxinos, Michael Brown, Yan Guo, Colleen Ludka, Colleen Hadigan, Richard.
Interactive Workshop “HIV Cure 101”: Challenges in identifying and targeting the HIV reservoir Sarah Palmer Centre for Virus Research Westmead Millennium.
Controversies in HIV Cure Research Debate 1. Is there ongoing replication under HAART? Mario Stevenson and Frank Maldarelli Moderator: Steve Deeks.
The Role of Mast Cells and CD117 in the Spread of HIV-1 Particles in Vitro Stacey Baker, Department of Biology, York College Project Summary Little is.
Cell- and Tissue-based Measures of Viral Persistence Are Associated with Immune Activation and PD-1-Expressing CD4+ T cells H Hatano 1, V Jain 1, PW Hunt.
Immune correlates of unusual control of viral replication after cessation of HAART Ellen Van Gulck 1, Leo Heyndrickx 1, Céline Merlin 1, Sandra Coppens.
HIV Drug Resistance Program NCI–Frederick Targeting ‘Residual HIV’ In Its Reservoirs: Where We Are And Where Do We Go? HIV Reservoirs Workshop Vienna,
Persistent low-level viremia despite clinically successful antiretroviral therapy appears correlated with more frequent resting CD4+ T cell Infection NM.
Perspectives on XMRV and Related Retroviruses John M. Coffin Endogenous proviruses Receptor usage Endogenous proviruses Receptor usage HIV Drug Resistance.
Viral Tissue Reservoirs Are Determined Early and Little Viral RNA Is Detected during Suppression in the Macaque Model Zandrea Ambrose, Ph.D. Division of.
Plate 36 Retroviruses.
M. Ekstrand 1,2,3, A. Shet 2,4, S. Chandy 4, G. Singh 4, R. Shamsundar 4, V. Madhavan 5, S. Saravanan 5, N. Kumarasamy 5 1 University of California, San.
Phylodynamically Estimated HIV Diversification Rates Reveal Prevention of HIV-1 by Antiretroviral Therapy Jeffrey B. Joy, Richard H. Liang, Rosemary M.
The Use of Pooled Viral Load Testing to Identify Antiretroviral Treatment Failure Davey Smith 1, Susanne May 2, Josué Perez-Santiago 1, Matthew Strain.
Sporadic excesses of unintegrated HIV DNA can occur in HIV+ patients on HAART Una O’Doherty University of Pennsylvania.
Abstract The major homology region (MHR) is a highly conserved sequence in the Gag gene of all retroviruses, including HIV-1. Its role in assembly is unknown,
Potential Utility of Tipranavir in Current Clinical Practice Daniel R. Kuritzkes, MD Director of AIDS Research Brigham and Woman’s Hospital Division of.
HBV (chronic) HIV ~400 million chronically infected
HIV: Science, Sex and Society. Lecture 1. Mechanisms of viral persistence in the face of antiviral therapy. Mario Stevenson, Ph.D Department of Medicine.
Robert F. Siliciano, MD, PhD Professor of Medicine The Johns Hopkins University School of Medicine Baltimore, Maryland Update on HIV Cure Research FORMATTED:
Estimating the population impact of homelessness on HIV viral suppression among people who use drugs Brandon DL Marshall, 1 Beth Elson, 1 Sabina Dobrer,
HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.
INVESTIGATING THE FITNESS BENEFIT OF REVERSE TRANSCRIPTASE (RT) MUTATION A62V CO-OCCURRING WITH M184V AND K65R IN HIV-1 SUBTYPE C Duncan T Njenda (MSc)
ACTG 5142: First-line Antiretroviral Therapy With Efavirenz Plus NRTIs Has Greater Antiretroviral Activity Than Lopinavir/Ritonavir Plus NRTIs Slideset.
First-Line Treatment of HIV Infection With Either NNRTI- or PI-Based Regimens Effective for Long-term Disease Control Slideset on: MacArthur RD, Novak.
Adefovir Suppresses HBV DNA Levels in Lamivudine-Resistant HIV/HBV Patients Slideset on: Benhamou Y, Thibault V, Vig P, et al. Safety and efficacy of adefovir.
Rilpivirine-TDF-FTC versus Efavirenz-TDF-FTC STaR Trial
The impact of treatment duration on defective and expanded identical HIV genomes in T cell subsets from peripheral blood and tissues Eunok Lee.
Prolonged HIV-1 Remission and Viral Rebound in an Individual Treated During Hyperacute Infection Timothy Henrich, Hiroyu Hatano, Alison Hill, Oliver Bacon,
Interim Analysis of a 3-Year Follow-up Study of NS5A and NS3 Resistance-Associated Variants After Treatment With Grazoprevir-Containing Regimens in Patients.
Emory University School of Medicine Department of Medicine
No Evidence Of Ongoing Replication In Tissue Compartments During cART
Virological and immunological efficacy of regimen including MVC
HIV Cure: Current Status and Future Perspectives
Conflict of Interest No conflicts of interest to declare.
Switch to RPV-TDF-FTC from Ritonavir-boosted PI Regimen SPIRIT STUDY
Etravirine versus Protease Inhibitor in ARV-Experienced TMC 125-C227
Switch from EFV plus ABC-3TC to EFV-TDF-FTC ROCKET-1 Trial
High IFN-γ/IL-10 Expression Ratio and Increased Frequency of Persistent Human T-Cell Lymphotropic Virus Type 1-Infected Clones Are Associated with Human.
Once Daily Etravirine versus Efavirenz in Treatment-Naive SENSE Trial
Dolutegravir versus Raltegravir in Treatment Experienced SAILING Study
Christine M. Fennessey, Ph.D AIDS and Cancer Virus Program
Atazanavir + ritonavir vs. Lopinavir-ritonavir CASTLE Study
HEATHER Feedback Meeting
Switching the NRTI Backbone to Tenofovir DF-Emtricitabine TOTEM
Balancing selection characterizes both MAE genes and cell type-specific genes (expressed in either nsc or asl but not in both). Balancing selection characterizes.
Figure 3 Monitoring clonal evolution using liquid biopsies
Changes in HIV-1 Co-receptor Tropism for Patients Participating in the Maraviroc MOTIVATE 1 and 2 Clinical Trials E van der Ryst and M Westby Pfizer Global.
by Andrew D. Redd, Ava Avalos, and Max Essex
Dorcas Obori-Yeboah and team
Quantitative analysis of the latent reservoir during treatment interruption. Quantitative analysis of the latent reservoir during treatment interruption.
Comparisons of the circulating latent reservoir and rebound viruses.
O. Turriziani, M. Andreoni, G. Antonelli 
Drug-resistant human immunodefiency virus
Volume 140, Issue 3, Pages e12 (March 2011)
Changes in HIV-1 Co-receptor Tropism for Patients Participating in the Maraviroc MOTIVATE 1 and 2 Clinical Trials E van der Ryst and M Westby Pfizer Global.
Volume 21, Issue 4, Pages e4 (April 2017)
What Integration Sites Tell Us about HIV Persistence
Figure 2. Technique overview
Volume 158, Issue 5, Pages (August 2014)
Double Trouble: HIV Latency and CTL Escape
Alex Sigal, David Baltimore  Cell Host & Microbe 
Pyoverdine production measured as RFUs standardized by OD significantly decreases with length of infection in years. Pyoverdine production measured as.
Fig. 3. The effect of VRC01 infusion on virus load in plasma and blood CD4 T cells during ART. The effect of VRC01 infusion on virus load in plasma and.
Differential Detection of M184V/I Between Plasma Historical HIV Genotypes and Proviral DNA from PBMCs N Margot, R Ram, IR McNicholl, R Haubrich, C Callebaut.
HIV Resistance in the Context of PrEP
HIV-1 Vif Adaptation to Human APOBEC3H Haplotypes
Rapid Detection of HIV-1 subtype C Integrase resistance mutations by the Use of High-Resolution Melting Analysis Tendai Washaya BSc, Msc. Pre-PhD Student.
Presentation transcript:

A HIGHER FRACTION OF DRUG RESISTANT PROVIRUSES EXPRESS UNSPLICED HIV RNA DURING ART COMPARED TO THE ARCHIVAL WILD-TYPE PROVIRUSES THAT COMPRISE THE HIV-1 RESERVOIR Mary Kearney NCI - Frederick HIV Dynamics and Replication Program

Conflict of Interest No conflicts of Interest to declare

Background We previously reported that about 5% of cells within clonally expanded populations are “actively-infected” (actively transcribing unspliced HIV RNA) and >90% are latently-infected (Musick, et al. CROI 2017). The fractions were not different for clones that carry replication-competent proviruses vs. those that have defective proviruses. Question How does HIV RNA expression in clones differ from expression in cells infected with proviruses that are resistant to the ART regimen?

Evaluated Proviral Expression in Patient #1 (Maldarelli, et al Evaluated Proviral Expression in Patient #1 (Maldarelli, et al. & Hughes, Science, 2014 and Simonetti, et al. & Maldarelli PNAS, 2016) SGS on plasma virus > 50 copies/mL < 50 copies/mL ABC+3TC+EFV Treatment Interruptions Treatment Failure AMBI-1 Single integration sites Small clones Large clones Results from Integration Sites Assay (ISA) What fraction of cells with drug resistant proviruses express HIV RNA during ART? How does this compare to cells with WT proviruses in the same sample?

Mean fraction of HIV expressing cells Higher Fraction of Expressing Cells in Drug Resistant Populations vs. Wild-Type Clones The fraction of cells that were actively-infected vs. latently infected was determined using the CARD-SGS assay (Wiegand, et al. & Kearney PNAS, 2017)  Population Type Mean fraction of HIV expressing cells p valuea Cells with WT proviruses 4.5% 8 x 10-14 Cells with DR proviruses 19.2% a Mann-Whitney test

Higher Levels of Expression from Drug Resistant Proviruses vs Higher Levels of Expression from Drug Resistant Proviruses vs. Wild-Type Clones Low levels of expression in cells with WT proviruses p value = 0.006 2-tail Fisher Exact test High levels of expression in some cells that have drug resistant proviruses

Conclusions The fraction and levels of proviral expression were significantly higher in cells with drug resistant variants than those with wild-type proviruses These findings show that ART can select both for cells infected before ART initiation that either do not express HIV RNA or express at low levels and for cells infected recently with drug-resistant viruses that express higher levels of HIV RNA.

Thank you to the NIH participant and his family! Acknowledgements University of Pittsburgh John Mellors Michele Sobolewski Francis Hong Joshua Cyktor Lou Halvas National Cancer Institute Andrew Musick Jon Spindler Frank Maldarelli Francesco Simonetti Steve Hughes William McManus Ann Wiegand Val Boltz Michael Bale Thank you to the NIH participant and his family! Leidos BioMedical Wei Shao Brandon Keele Carolyn Reid Joseph Meyer Tufts University John Coffin NCI - Frederick HIV Dynamics and Replication Program

10,450 Infected Cells Analyzed Proviral Expression Is Not Different in Clones with Replication-Competent vs. Defective Proviruses Replication Competent Mean fraction expressing = 4% Defective Mean fraction expressing = 4% No Outgrowth Mean fraction expressing = 12% % of cells within each clone that contain ca-HIV RNA Clone ID 10,450 Infected Cells Analyzed